rethinkPeptides Search
Menu
Study breakdown

CJC-1295 in Humans: Single Injection Sustains GH and IGF-1 Elevation for Up to 2 Weeks

RCTStrong evidence
The takeaway

A single subcutaneous injection of CJC-1295 in healthy humans produced dose-dependent, sustained GH and IGF-1 elevation lasting up to 2 weeks — the longest-acting GH-axis restoration from a single peptide dose.

Key finding

Single SC CJC-1295 injection in healthy adults produced dose-dependent sustained GH pulsatility and IGF-1 elevation lasting 6-14 days depending on dos

What the researchers found

Single SC CJC-1295 injection in healthy adults produced dose-dependent sustained GH pulsatility and IGF-1 elevation lasting 6-14 days depending on dose, with 2-3 fold IGF-1 increase maintained for up to 2 weeks — the most sustained GH-axis restoration from a single peptide dose.

Why it matters

Relevant for cjc-1295, hormone-optimization.

How the study worked

RCT study on cjc-1295, hormone-optimization.

What this study cannot tell us

See abstract.

How to read the evidence

strong evidence.

When this study was published

Published in 2006.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.
  • Clinical translation to evaluate.

Common questions

What was studied?
CJC-1295 in Humans: Single Injection Sustains GH and IGF-1 Elevation for Up to 2 Weeks
What was found?
A single subcutaneous injection of CJC-1295 in healthy humans produced dose-dependent, sustained GH and IGF-1 elevation lasting up to 2 weeks — the longest-acting GH-axis restoration from a single peptide dose.

Read the original research

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

The Journal of clinical endocrinology and metabolism, 91(3), 799-805

Citation

Teichman, Sam L; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 91(3), 799-805.